Page 4 - Heart Failure Guidelines
P. 4

Pediatric Heart Failure Guidelines

               Table of Contents

               Preface ...................................................................................................................................... 3
               Heart Failure - General Considerations ...................................................................................... 6
                  Initial Evaluation ..................................................................................................................... 6
                  Disease Staging for Infants & Children ................................................................................... 6
                  Symptom Severity Classification ............................................................................................. 7
                  Genetics Evaluation ................................................................................................................ 7
                  Medications ............................................................................................................................ 8
                  Anticoagulation ......................................................................................................................12
                  Nutrition .................................................................................................................................12
                  Exercise ................................................................................................................................13
                  Advanced Therapies ..............................................................................................................14
                  Follow-up Schedule ...............................................................................................................15

               Dilated Cardiomyopathy (DCM) ................................................................................................16
                  Additional Evaluation for DCM ...............................................................................................16
                  Medical Management DCM ...................................................................................................16
                  Follow-up Schedule for DCM .................................................................................................16

               Hypertrophic Cardiomyopathy (HCM) .......................................................................................17
                  Additional Diagnostic Evaluation for HCM .............................................................................17
                  Management HCM ................................................................................................................17
                  References ............................................................................................................................18
                  Obstruction Algorithm ............................................................................................................19
                  ICD Algorithm ........................................................................................................................20
                  Follow-up Schedule for Hypertrophic Cardiomyopathy ..........................................................21

               Restrictive Cardiomyopathy (RCM) ...........................................................................................21
                  Additional Evaluation for RCM ...............................................................................................21
                  Medical Management RCM ...................................................................................................21
                  Follow-up Schedule for Restrictive Cardiomyopathy ..............................................................22

               Non-Compaction Cardiomyopathy (LVNC) ................................................................................23
                  Additional Evaluation for LVCN .............................................................................................23
                  Medical Management for LVCN .............................................................................................23
                  Follow-up Schedule for LVCN ...............................................................................................23
               Congenital Heart Disease with Heart Failure .............................................................................24
                  Additional Evaluation for CHD with Heart Failure ...................................................................24
                  Management and Long-Term Follow-up for CHD with Heart Failure ......................................24
               Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) ......................................................25

                  Additional Evaluation for ARVC .............................................................................................25
                  Medical Management for ARVC ............................................................................................25
                  Follow up for ARVC ...............................................................................................................25
               Chemotherapy Induced Cardiomyopathy ..................................................................................26




               Updated 9/21/2018                                                                       page 4
   1   2   3   4   5   6   7   8   9